133053-70-0

Basic information

• Product Name: 1H-Indole, 7-Methyl-6-nitro-
• Synonyms: 1H-Indole, 7-Methyl-6-nitro-;7-Methyl-6-nitro 1H-indole
• CAS NO: 133053-70-0
• Molecular Formula: C9H8N2O2
• Molecular Weight: 176.17202
• Mol File: 133053-70-0.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indole, 7-Methyl-6-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole, 7-Methyl-6-nitro-(133053-70-0)
• EPA Substance Registry System: 1H-Indole, 7-Methyl-6-nitro-(133053-70-0)

Safety Data

• Hazardous Substances Data: 133053-70-0(Hazardous Substances Data)

Usage

Structure

A derivative of the heterocyclic compound indole with a nitro group at the 6th position and a methyl group at the 7th position of the indole ring.

Usage

Commonly used in the synthesis of various pharmaceuticals and agrochemicals due to its versatile reactivity and pharmacological properties.

Biological activities

Studied for its potential antimicrobial and anticancer properties, making it an important component in medicinal chemistry research.

Upstream product

• 208510-90-1 7-methyl-6-nitroindoline 
• 84-58-2 2,3-dicyano-5,6-dichloro-p-benzoquinone 
• 87-62-7 2,6-dimethylaniline 
• 67083-28-7 2,6-dimethyl-3-nitroaniline 
• 133053-69-7 methyl N-(2,6-dimethyl-3-nitrophenyl)-formimidate 

Downstream Products

• 208510-99-0 7-methyl-1H-indol-6-amine 

Relevant articles and documents

2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure: wherein: a) R1 is hydrogen; or alkyl; bond (a) is a single or a double bond; b) R2 and R3 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; c) R4, R5 and R6 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino; halo; and 2-imidazolinylamino; and wherein one and only one of R4, R5 and R6 is 2-imidazolinylamino; d) R7 is selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; e) the compound is not 4-(2-imidazolinylamino)indole; enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, and pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for treating disorders modulated by alpha-2 adrenoceptors.